CHANDAN (CHANDAN) fundamentals
CHANDAN is a listed company, part of the Healthcare sector, listed on the NSE as CHANDAN (ISIN INE0B2N01016). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What CHANDAN does
Chandan Healthcare Limited is an India-based company, which is engaged in the business of operating medical stores. The Company offers a range of pharmaceutical products including medical consumables such as tablets, capsules, syrups, ointments, and a variety of dosage forms, including liquids, solids, and semisolids. It also provides essential items, such as injectables and inhalers to meet the diverse healthcare needs of its customers. Its services are designed to detect early symptoms of diseases and support disease prevention by monitoring various health indicators. Its laboratory has several departments, including clinical biochemistry; clinical pathology; histopathology, cytopathology and immune histochemistry; microbiology and serology; molecular pathology, and cytogenetics. It receives routine and specialized testing requests and related samples for testing from its central reference laboratories, satellite laboratories and collection centers.
Valuation and market data
| Last close | ₹198.60 |
|---|---|
| Market capitalisation | ₹433 crore |
| Enterprise value | ₹454 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.43 |
| Price to sales (TTM) | 1.47 |
| Book value per share | ₹57.94 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹161 crore | ₹34 crore | ₹25 crore | 0.00 |
| Mar 2025 | ₹130 crore | ₹28 crore | ₹21 crore | 10.10 |
| Mar 2024 | ₹101 crore | ₹21 crore | ₹16 crore | 8.01 |
| Mar 2023 | ₹76 crore | ₹5 crore | ₹4 crore | 2.02 |
| Mar 2022 | ₹72 crore | ₹-1 crore | ₹-1 crore | -0.36 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 49.6% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 5.1% |
| Retail and others | 45.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.